Masha Zeltsman1, Marissa Mayor1, David R Jones1, Prasad S Adusumilli2. 1. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA. 2. Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA; Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, USA. Electronic address: adusumip@mskcc.org.
Abstract
BACKGROUND: The purpose of this study was to systematically review clinically translatable immunotherapeutic agents that are delivered regionally for solid malignancies. DATA SOURCES: PubMed and ClinicalTrials.gov were searched for published and registered clinical trials, respectively. The search yielded 334 relevant publications, of which 116 articles were included for review after exclusion criteria were applied. CONCLUSIONS: There has been an increase in the regional administration of cell-based and viral vector-based clinical trials over the last 5 years. Surgical interventions have been developed for intrapleural, intracranial, intraperitoneal, and intratumoral routes of access to enhance the local delivery of these therapies. Multimodality therapies that combine regional immunotherapy with other local and systemic therapies are demonstrating continued growth as the field of immunotherapy continues to expand.
BACKGROUND: The purpose of this study was to systematically review clinically translatable immunotherapeutic agents that are delivered regionally for solid malignancies. DATA SOURCES: PubMed and ClinicalTrials.gov were searched for published and registered clinical trials, respectively. The search yielded 334 relevant publications, of which 116 articles were included for review after exclusion criteria were applied. CONCLUSIONS: There has been an increase in the regional administration of cell-based and viral vector-based clinical trials over the last 5 years. Surgical interventions have been developed for intrapleural, intracranial, intraperitoneal, and intratumoral routes of access to enhance the local delivery of these therapies. Multimodality therapies that combine regional immunotherapy with other local and systemic therapies are demonstrating continued growth as the field of immunotherapy continues to expand.
Authors: Kyuichi Kadota; Jun-Ichi Nitadori; Hideki Ujiie; Daniel H Buitrago; Kaitlin M Woo; Camelia S Sima; William D Travis; David R Jones; Prasad S Adusumilli Journal: J Thorac Oncol Date: 2015-09 Impact factor: 15.609
Authors: Neil L Berinstein; Gregory T Wolf; Paul H Naylor; Lorraine Baltzer; James E Egan; Harvey J Brandwein; Theresa L Whiteside; Lynn C Goldstein; Adel El-Naggar; Cecile Badoual; Wolf-Herve Fridman; J Michael White; John W Hadden Journal: Cancer Immunol Immunother Date: 2011-11-06 Impact factor: 6.968
Authors: A Blancher; F Roubinet; A S Grancher; M Tremoulet; A Bonaté; M B Delisle; J P Calot; C Pourreau; C Franks; J Ducos Journal: Eur Cytokine Netw Date: 1993 Sep-Oct Impact factor: 2.737
Authors: M G Muto; N J Finkler; A I Kassis; A E Howes; L L Anderson; C C Lau; V R Zurawski; K Weadock; S S Tumeh; P Lavin Journal: Gynecol Oncol Date: 1992-06 Impact factor: 5.482
Authors: Ronald D Alvarez; Warner K Huh; M B Khazaeli; Ruby F Meredith; Edward E Partridge; Larry C Kilgore; William E Grizzle; Sui Shen; J Max Austin; Mack N Barnes; Delicia Carey; Jeffrey Schlom; Albert F LoBuglio Journal: Clin Cancer Res Date: 2002-09 Impact factor: 12.531
Authors: Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos Journal: N Engl J Med Date: 2003-01-16 Impact factor: 91.245
Authors: Vera S Donnenberg; Patrick L Wagner; James D Luketich; David L Bartlett; Albert D Donnenberg Journal: Front Immunol Date: 2022-02-11 Impact factor: 7.561